The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing

BACKGROUND: Natalizumab is efficacious in the treatment of relapsing-remitting multiple sclerosis. All patients receive the same treatment regimen of 300 mg every 4 weeks, despite differences in pharmacokinetics between individual patients. OBJECTIVE: To give neurologists insight into natalizumab co...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mult Scler
Main Authors: van Kempen, Zoé LE, Leurs, Cyra E, Witte, Birgit I, de Vries, Annick, Wattjes, Mike P, Rispens, Theo, Killestein, Joep
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2017
Assuntos:
Original Research Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5971363/
https://ncbi.nlm.nih.gov/pubmed/28485678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458517708464
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares